EB-105

N/A

Report date: 2024/07/16 17:47:00

Base Information

Drug NameEB-105
Drug Alias NameEB-105
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionVascular endothelial growth factor A inhibitorsVascular endothelial growth factor B inhibitorsPlacental Growth Factor inhibitors +[5] 
TargetsVascular endothelial growth factor AVascular endothelial growth factor BPlacental Growth Factor +[5] 
Therapy Area/IndicationsDiabetic macular oedemaDiabetic Retinopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesEluminex Biosciences (Suzhou) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEluminex Biosciences (Suzhou) LtdEluminex Biosciences Inc
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaDiabetic Retinopathy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A